An ionic hydrogel with stimuli-responsive, self-healable and injectable characteristics for the targeted and sustained delivery of doxorubicin in the treatment of breast cancer

Designing stimuli-responsive therapeutic scaffolds to deliver hydrophobic chemo drugs with controlled and sustained release at the tumor site would be promising in cancer treatment. In a quest for the stimuli-responsive drug delivery system with sustained release, herein we have fabricated an active pharmaceutical ingredient-based ionic liquid (IL) based hydrogel with self-healable and injectable properties. The ionic hydrogel makes a localized, long-term co-delivery system with self-healable, injectable, and stimuli-responsive properties. Further, the smart hybrid ionic hydrogel was constructed through encapsulating doxorubicin (DOX) within the 3D matrix of the ionic hydrogel, which response to intracellular biological stimuli (e.g., pH and temperature) and releases DOX in 57 h. Experimental results of IL-IL and IL-DOX interactions are supported through Density Functional Theory (DFT) calculations. In vitro cellular studies revealed that the DOX-loaded hybrid ionic hydrogel shows a synergistic anticancer effect against MCF-07 cells. These results demonstrate the ability of the ionic hydrogel as a promising candidate for local cancer therapeutics.

Automated summary

The researchers developed a stimuli-responsive drug delivery system utilizing an active pharmaceutical ingredient-based ionic liquid hydrogel, which exhibits self-healing and injectable properties for controlled and sustained release of hydrophobic chemo drugs at the tumor site. The hybrid ionic hydrogel, loaded with doxorubicin, demonstrates a synergistic anticancer effect against MCF-07 cells, highlighting its potential as a promising candidate for local cancer therapeutics.